Added 3 days ago Drug news
Phase III study of Crysvita demonstrates superiority in X-linked hypophosphatemia.- Ultragenyx Pharma + Kyowa Hakko Kirin
Ultragenyx Pharmaceutical, Kyowa Hakko Kirin, and Kyowa Kirin International announced positive results of a 64-week efficacy and safety analysis of...
Added 20 days ago Drug news
Phase III success for Ultomiris in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome . Alexion Pharma
Alexion Pharmaceuticals, Inc. announced that the Phase III study of Ultomiris (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its...
Added 1 month ago Drug news
Positive results from three phase III studies of roxadustat for anemia in patients with chronic kidney disease. FibroGen + AstraZeneca
FibroGen, Inc. announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Anaemia and iron deficiency are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents.
Added 10 months ago
This is a comprehensive but pragmatic new guideline and focuses on the accurate diagnosis, delineation of severity types and subsequent management of this rare haematological condition.
Added 3 years ago
The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with primary autoimmune haemolytic anaemia (AIHA).
Added 11 months ago
Our meta-analysis published in 2010 provided evidence that low levels of serum albumin (hypoalbuminemia) are a significant independent predictor of acute kidney injury (AKI) and death following AKI.
Added 1 year ago
Could testosterone therapy in hypogonadal men ameliorate anemia, a cardiovascular risk factor? An observational, 54-week cumulative registry study.
In this study we investigated if testosterone undecanoate attenuates anemia and the risk of cardiovascular disease in patients with hypogonadism.
Added 1 year ago
Hemolytic-uremic syndrome (HUS) is the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI); the main cause of multi-organ failure is related to thrombotic microangiopathy (TMA).
Added 1 year ago
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in...
Added 7 months ago
A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to subjects with either beta-thalassemia major or severe sickle cell disease (SCD).
Added 5 years ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee